Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer

References

• Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline. J Urol. 2019;201(3):528–534.
   PubMed Web of Science ®Google Scholar
• Lee WR, Dignam JJ, Amin MB, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34(20):2325–2332.
   PubMed Web of Science ®Google Scholar
• Dearnaley D, Syndikus I, Mossop H, CHHiP Investigators, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–1060.
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience. Int J Radiat Oncol Biol Phys. 2007;68(5):1424–1430.
   PubMed Web of Science ®Google Scholar
• Catton CN, Lukka H, Gu CS, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35(17):1884–1890.
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Michalski JM, Mendenhall NP, et al. Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer. 2014;120(7):1076–1082.
   PubMed Web of Science ®Google Scholar
• Grewal AS, Schonewolf C, Min EJ, et al. Four-Year outcomes from a prospective phase II clinical trial of moderately hypofractionated proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2019;105(4):713–722.
   PubMed Web of Science ®Google Scholar
• University of Florida. A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer (COMPPARE) clinicaltrials.gov2018. [cited January 8, 2021]. Available from: https://clinicaltrials.gov/ct2/show/NCT03561220.
   Google Scholar
• Massachusetts General Hospital. Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer (PARTIQoL) clinicaltrials.gov2012. [cited January 8, 2021]. Available from: https://clinicaltrials.gov/ct2/show/NCT01617161.
   Google Scholar
• Henderson RH, Bryant C, Hoppe BS, et al. Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer. Acta Oncol. 2017;56(7):963–970.
   PubMed Web of Science ®Google Scholar
• Vapiwala N, Wong JK, Handorf E, et al. A pooled toxicity analysis of moderately hypofractionated proton beam therapy and intensity-modulated radiation therapy in early stage prostate cancer patients. Int J Radiat Oncol Biol Phys. 2021;110(4):1082–1089.
   PubMed Web of Science ®Google Scholar
• Mendenhall NP, Li Z, Hoppe BS, et al. Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(1):213–221.
   PubMed Web of Science ®Google Scholar
• Mendenhall NP, Hoppe BS, Nichols RC, et al. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014;88(3):596–602.
   PubMed Web of Science ®Google Scholar
• Bryant C, Smith TL, Henderson RH, et al. Five-Year biochemical results, toxicity, and Patient-Reported quality of life after delivery of dose-escalated image guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2016;95(1):422–434.
   PubMed Web of Science ®Google Scholar
• Abu-Gheida I, Reddy CA, Kotecha R, et al. Ten-Year outcomes of moderately hypofractionated (70 Gy in 28 fractions) intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2019;104(2):325–333.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Ando K, Kato TA, et al. Difference in degree of sub-lethal damage recovery between clinical proton beams and X-rays. Radiat Prot Dosimetry. 2019;183(1–2):93–97.
   PubMed Web of Science ®Google Scholar
• Paganetti H. Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer. Phys Med Biol. 2014;59(22):R419–72.
   PubMed Web of Science ®Google Scholar
• Slater JM, Slater JD, Kang JI, et al. Hypofractionated proton therapy in early prostate cancer: results of a phase I/II trial at Loma Linda University. Int J Part Ther. 2019;6(1):1–9. DOI:https://doi.org/10.14338/IJPT-19-00057
   Google Scholar
• Hamstra DA, Mariados N, Sylvester J, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys. 2017;97(5):976–985.
   PubMed Web of Science ®Google Scholar